Mods can feel free to remove the thread.
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
National Centre for Neuroimmunology and Emerging Diseases - NCNEDLike Page
3 hrs ·
NCNED describes calcium signalling disorder in CFS/ME
Our latest article (Nguyen et al., 2017) shows that certain ion channel receptors (called transient receptor potential ion channels or TRPs) responsible for calcium signalling in Natural Killer (NK) cells are defective, even when stimulated with their natural ligand.
We have used NK cells as a model to illustrate this pathology in all cells.
These current results indicate this ion channel is not functioning correctly and unable to modulate calcium in people with CFS/ME even when stimulated with its natural ligand, pregnenalone sulphate, under strictly controlled conditions.
As there are multiple TRP channels and autonomic receptors, we have identified these may also be implicated in this disabling illness.
We have clear evidence from at least two separate studies that these ion channels, as well as calcium and its signalling, are dysfunctional in CFS/ME.
Our team at NCNED is now targeting pharmacotherapeutics to treat this disorder.
NCNED is pleased to acknowledge all our donors and benefactors. Special thanks to the Stafford Fox Medical Research Foundation, Mr Douglas Stutt and the Queensland Government for their unfailing support.
Our team at NCNED is now targeting pharmacotherapeutics to treat this disorder.
I noted this from the press release today:
I noted this from the press release today:
I looked at the FB Page and wish I could understand it better so am asking for help from a group I belong to for people with my same CA+ autoantibody (except we cover a vast variety of diagnoses and symptoms). Right now the main treatments are things like IVIG, RTX and cancer screenings. But this may be unrelated until I can understand the article better!
I noted this from the press release today:
Do we know what kind of drugs?? I just got a non–dihydropyridine calcium channel blocker called Verapamil to treat pain/ME symptoms.
Does anyone understand if this study is related to that drug in any way?? I don't understand any of this.
How would this paper relate to someone having autoantibodies that attack the CA+ channel or a calcium channelopathy?
Does anyone understand if this study is related to that drug in any way?? I don't understand any of this.
I think that is an important point, one I have tried to push. If validated this kind of thing will probably have the greatest impact on the brain, but through circulatory factors it may affect every single tissue in addition to the nearly universal expression of these types of receptors. In other words its about a multisystemic impact.This is not likely to be peculiar to NK cells since these receptors are present on many cell types, it's just that they chose to study NK cells.